Summary Report of Consolidated Financial Results
For the Nine Months Period ended December 31, 2014
February 12, 2015
stCompany name: NIPRO CORPORATION
TSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Yoshihiko Sano, President and Representative Director
Contact person: Kimihito Minoura, Director and General Manager of Corporate Planning Headquarters
TEL: (06)6372-2331
Filing date of quarterly reporting: February 13, 2015
Payment date of cash dividends: Supplemental material on quarterly reporting: No
Presentation on quarterly results: No(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Nine Months ended December 31, 2014 (From April 1, 2014 to December 31, 2014)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
9 months ended December 31, 2014
240,101
7.9
13,72633.3
18,49055.2
14,520223.2
9 months ended December 31, 2013
222,61922.9
10,295
5.1
11,9104.0
4,493 (56.7)
Note: Comprehensive income

9 months ended December 31, 2014: 19,079 million yen ((25.8)%) 9 months ended December 31, 2013: 25,724 million yen (-%)

9 months ended December 31, 2014
9 months ended December 31, 2013

Earnings per share
Yen
95.63
28.18

(2) Consolidated Financial Position
Total Assets
Millions of yen
9 months ended December 31, 2014
656,843
Year ended March 31, 2014
619,654
Note: Equity

2.

Diluted Earnings per share
Yen
85.82
25.27

Net Assets
Millions of yen
152,945
135,960

9 months ended December 31, 2014: 141,893 million yen

Equity Ratio
%
21.6
20.2

Year ended March 31, 2014: 125,426 million yen

Dividends

Year ended March 31, 2014
Year ending March 31, 2015
Year ending March 31, 2015
(Forecast)

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
16.00
14.50
18.00
-

First-quarter
Yen-

Annual Dividends

Yen
30.50

14.50

32.50

Note: Revisions to the forecast of cash dividends in the current quarter: No
3.

Forecast of Consolidated Financial Results for the Year ending March 31, 2015 (From April 1, 2014 to March 31, 2015)(Note: The % displays in the line of year ending March 31, 2015 show increase/decrease ratio against the year ended March 31, 2014)

Operating
IncomeNet Sales
Millions of yen%

Millions of yen

Ordinary Income%

Millions of yen%

330,000 9.7
20,00062.7
18,60056.1
Note: Revisions to the forecast of consolidated financial results in the current quarter: No
Year ending March 31, 2015

Net Income
Millions of yen

10,400%263.4

Earnings
per Share
Yen
68.97

*Notes(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0Removal: 0(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No[3] Change in accounting estimate: No[4] Restatement: No
Note: More information can be found in P.4 “2. Summary (Other) Information, (3) Changes in Accounting Policies andAccounting Estimate and Restatement” in the attachment.
(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
9 months ended December 31, 2014: 171,459,479 sharesYear ended March 31, 2014: 171,459,479 shares[2] Number of treasury stock at end of the period:
9 months ended December 31, 2014:

17,052,828 sharesYear ended March 31, 2014:

20,730,973 shares[3] Average number of shares during the period:
9 months ended December 31, 2014: 151,839,221 shares

9 months ended December 31, 2013: 159,442,744 shares

Note: Number of the treasury stocks as of December 31, 2014 included 990,300 shares, and as of March 31, 2014
included 1,187,500 shares owned by Trust Account E*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.
*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.4“1. Qualitative Information for the Nine-Month Period Ended December 31, 2014, (3) Commentary on
Forward-Looking Statements Including Forecast of Consolidated Financial Results” in the attachment.

Table of Contents

1.

2.

3.

Qualitative Information for the Nine-Months Period ended December 31, 20142

(1) Commentary on Business Results

2(2) Analysis Concerning Financial Position

3(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results

4

Summary (Other) Information

4(1) Changes in Significant Consolidated Subsidiaries

4(2) Accounting Treatments Simplified or Unique for Preparation

4(3) Changes in Accounting Policies and Accounting Estimate and Restatement

4

Consolidated Financial Statements

5(1) Quarterly Consolidated Balance Sheets

5(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income

7

Quarterly Consolidated Statements of Income

7

Quarterly Consolidated Statements of Comprehensive Income

7(3) Notes Regarding Consolidated Financial Statement

8

Notes regarding going concern

8Notes regarding significant changes in the amount of shareholders’ equity

8

Segment Information

8-1-

1. Qualitative Information for the Nine-Month Period Ended December 31, 2014
(1) Commentary on Business Results
During the nine months of the fiscal year under review, the global economy generally remained on a gradual recovery
trend since an improvement in personal consumption led stable recovery in the United States and Europe also showed
continued economic recovery. In China and emerging countries, a sense of uncertainty is increasing due to declining
economic growth rates. On the other hand, the Japanese economy showed continued improvement although there wererapid yen depreciation and a fallback after the last-minute surge in demand before the consumption tax rate hike.
Under such circumstances, the Nipro Group has worked to improve operating results through its continued efforts to
expand sales and reduce costs.
As a result, consolidated sales for the nine-month period ended December 31, 2014 increased by 7.9% from the same
period of the previous year to 240,101 million yen. As for the profit, consolidated operating income increased by 33.3%
from the same period of the previous year to 13,726 million yen. Consolidated ordinary income, moreover, increased by
55.2% from the same period of the previous year to 18,490 million yen due to the foreign exchange gain for yen’s
depreciation. Consolidated net income increased by 223.2% from the same period of the previous year to 14,520 million
yen thanks to the record of gain on sales of investment securities and a decrease of income taxes.
The overview of the results for the current quarter period under review by business segment is as follows.
Effective from this reporting period, overseas glass department is reclassified from Medical-Related Business to
Glass-Related Business with the current classification.

(i)

Medical-Related BusinessLooking at the domestic market, the Medical Sales Division performed well with continued strength in sales and profits

of the drug-eluting balloon catheter “SeQuent® Please” in the field of vascular products and the fallback after the special
demand arose before the consumption tax rate hike was almost resolved in injection-transfusion products,
enteral-alimentation products and testing products. They also showed strong sales of HDF filter in dialysis product but it
is still difficult to solve the fallback after special demand. Sales and profits of the cardiovascular (CVS) products were in
the midst of the severe environment with the impact from competitors. On the other hand, for the Pharmaceutical Sales
Division, the competitive environment of domestic market became fiercer by the appearance of manufactures of original
drugs running sideline business though more expansion of the market can be expected with the promotion policy ofgeneric drugs. Under such situation, unit prices of drugs were declined due to a revision of their wholesale prices (selling
prices to wholesale dealers) following the revision in drug prices in April 2014, however, this was offset by favorable
influence of the government’s generic drug promotion measures following the revision of medical fees and addenda
listing items launched in December, and the sales remained stable. In addition, we have strengthened the sales
promotion to dispensing pharmacies, diagnosis procedure combination (DPC) and prescribers. Also we tried to increase
the share of drugs for oral and external use and worked harder for information offering activities of injectable drugs basedon the collaboration with pharmaceutical wholesaler and Medical Sales Division. However, large markets of new big
listing items have being continuously entered by over 30 competitors and initial sales of AG (authorized generic) allows tomarket occupation, that made the market price competition more intensified to impact significantly to sales and profit.
Regarding overseas sales, on the other hand, direct sales activities were promoted with enhancement of overseas
sales channel based on our concept of “local production for local consumption” and expanded our sales responding
immediately to demand from medical front. In addition, sales prices were reviewed throughout the world to improve our
profitability. Furthermore, yen’s depreciation against dollar and euro in foreign exchange market increasing export
profitability continuously resulted double-digit growth in sales and profit from the same period of the previous year. By
product, we have promoted academic activities through international societies or exhibition of dialysis or kidney disease
as well as enhanced dialysis product line, and consequently sales of the related products such as artificial kidneys(dialyzers) showed a strong increase. New overseas plants (in India, Indonesia, Bangladesh and Hefei) further improved
their production system and realized stable production expansion under established quality system to promote their sales
widely in their countries and surrounding areas. Especially production of dialyzers in India and Hefei plants has increasedsmoothly to contribute the sales increase and syringe from India and Indonesia plants has supported the sales growth.
As a result, net sales of this business increased by 7.3% from the same period of the previous year to 175,364 million
yen.

-2-

(ii)

Pharmaceutical-Related BusinessIn the Pharmaceutical-Related Business, we have promoted finely-tuned sales activities to win contracted businesses

by offering various contracted services such as contracted development based on our characteristic of development andsupply from packaging container such as vial, syringe and bag and support for value adding initiatives, in addition to ourconventional contracted manufacturing service. We have also worked to expand the contracted manufacturing businessthrough joint development with generic drug divisions and new drug development divisions of leading pharmaceuticalmanufacturers inside and outside of Japan. Furthermore, the self-developed blockbuster syringe preparations, shipmentof which started at the end of the previous fiscal year, contributed to the solid sales of this segment.
Sales of pharmaceutical containers as well as devices related to pharmaceutical preparation and administration werestrong thanks to our efforts to offer containers and systems suitable to each pharmaceutical product. Such efforts weremade to meet various needs in the medical front, including small-volume bags for antimicrobial agents and osteoporosis
drugs, materials for pre-filled syringes (plastic and glass), etc., on top of rubber stoppers for pharmaceutical and vaccine
use and containers for kit products. We developed the containers and systems by ourselves or through joint developmentwith pharmaceutical manufactures based on our processing technologies for plastics, rubbers, and metals. In addition,
under the government’s policy to curb medical expenses, we have worked together with domestic and foreign
pharmaceutical manufactures in enhancing comprehensive lifecycle management of pharmaceutical products, taking into
consideration the development of combination products, self-injection systems, and dosage form/administrating pathmodification in the future.
As a result, net sales of this business increased 11.8% from the same period of the previous year to 42,966 million yen.

(iii) Glass-Related BusinessIn the Glass-Related Business, adding to our conventional glass containers for medical use, we have promoted sales
activities to acquire new demands while high-valued vials were developed and distributed to support injectable
formulation with high stability.
In domestic glass department, we have continuously promoted our sales activities of vial with low alkali elution to the
medical and pharmaceutical industries and also increased the sales mainly in prefilled syringe. As for “Biwako Factory,” astate-of-the-art plant for glass containers for domestic medical use, with the purpose of further improving our quality
assurance system for good manufacturing practice (GMP), the factory was registered as medical equipment manufacturein December and started to prepare the introduction of glass products from overseas affiliated companies to Japan andestablish quality assurance system. Among other glass-related products, sales of glass for thermos bottles decreased
from the same period of the previous year due to weak domestic demand against the recovery of export. Whole sales ofthis department slightly decreased from the same period of the previous year.
Regarding overseas glass department, on the other hand, sales and profit of vial and ampoule have increased stably in
India and China under the changing of market that requires high-quality medical containers in developing countries. In
Europe and the United States, high-tech prefilled syringe has marked find sales.
As a result, net sales of this business increased 5.1% from the same period of the previous year to 21,686 million yen.

(iv) Other BusinessAmong other business, sales from the real-estate rental business were 83 million yen (down by 53.0% from the same
period of the previous year).

(2) Analysis Concerning Financial Position
Analysis Concerning the Conditions of Assets, Liabilities and Net Assets
Total assets increased by 37,189 million yen from the end of the previous year to 656,843 million yen. Current assets
increased by 27,937 million yen primarily due to an increase of 12,919 million yen in notes and accounts receivable-trade,and noncurrent assets increased by 9,251 million yen primarily due to an increase of 9,243 million yen in buildings andstructures.
Total liabilities increased by 20,204 million yen from the end of the previous year to 503,898 million yen. Current
liabilities decreased by 6,259 million yen primarily due to an decrease of 6,877 million yen in income taxes payable, andnoncurrent liabilities increased by 26,463 million yen primarily due to an increase of 28,302 million yen in long-term loans-3-payable.
Total net assets increased by 16,984million yen from the end of the previous year to 152,945 million yen. Shareholders’equity increased by 12,298 million yen and accumulated other comprehensive income increased by 4,168 million yen.

(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results
We expect that the global economy will continue to be on the gradual recovery trend. Similarly, in Japan, economic
activities will continue to gradually improve amid the easing of the fallback after the last-minute surge in demand before theconsumption tax rate hike.
Even under such circumstances, the Nipro Group will work to improve profits through its continued efforts to expand
sales and reduce production costs.
Foreign exchange gain is recorded in non-operating income by 6,327 million yen in the current period (from April 1,2014 to December 31, 2014), however, this amount is changeable based on the trends of exchange rate for the future.
Therefore, at this moment, we have not made any revision to the forecast of consolidated financial results for the year
ending March 31, 2015, which was announced on November 12, 2014.

2. Summary (Other) Information(1) Changes in Significant Consolidated Subsidiaries
N/A(2) Accounting Treatments Simplified or Unique for Preparation
N/A(3) Changes in Accounting Policies and Accounting Estimate and Restatement(Change in Accounting Policies)
Application of the Accounting Standard for Retirement Benefits and its Guidance
From the first quarter of the consolidated fiscal year under review, we adopted the “Accounting Standard for
Retirement Benefits” (ASBJ Statement No. 26, May 17, 2012; hereinafter referred to as the “Retirement Benefits
Standard”) and the “Guidance on Accounting Standard for Retirement Benefits” (ASBJ Guidance No. 25, May 17, 2012;
hereinafter referred to as the “Retirement Benefits Guidance”) with regard to the provisions specified under the main clauseof paragraph 35 of the Retirement Benefits Standard and paragraph 67 of the Retirement Benefits Guidance. The
calculation method of retirement benefit obligations and service costs was reviewed, the period attribution method of the
expected amount of retirement benefits was changed from a straight‐line attribution to a benefit calculation standard andthe decision method of the discount rate was changed from the way in which the number of years approximate to theaverage remaining service period of employees is used for the period of bonds that serves as thebasis for determining

the discount rate to the way in which a single weighted average discount rate is used to reflect the expected payment
period of retirement benefits and the amount for each expected payment period.
In applying the Retirement Benefits Standard and its Guidance, the effect of the changes in the calculation method ofretirement benefit obligations and service costs was adjusted in retained earnings at the beginning of the first quarter of theconsolidated fiscal year under review according to the transitional treatment set forth in the paragraph 37 of the Retirement
Benefits Standard.
As a result, net defined benefit liability decreased 150 million yen and retained earnings increased 97 million yen at the
beginning of the current quarterly period under review. This change had no impact on operaing income, ordinary income andincome before income taxes and minority interests in the current quarterly period under review.

-4-3. Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets](Millions of yen)
As ofMarch 31, 2014
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Net defined benefit asset
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-5-

As of
December 31, 2014

84,957103,179
59,517
10,96820,0007,354
12,154(2,010)296,119

93,917116,098
63,127
11,707
21,466
6,810
13,019(2,088)324,057

158,109(77,025)
81,083
192,277(135,012)
57,26523,3672,409(1,507)902
20,53437,683(29,242)8,440
191,593

169,714(79,387)
90,326207,304(145,595)
61,70821,3102,378(1,647)731
24,482
40,729(31,479)
9,250
207,81028,493443
13,27842,216

26,958337
15,28542,58265,50798
8,453
18,535(2,870)89,724
323,534
619,654

60,364
107
11,12013,788(2,987)
82,393332,786
656,843

(Millions of yen)
As ofMarch 31, 2013
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Current portion of convertible bond-type bonds
with subscription rights to shares
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Long-term loans payable
Lease obligations
Deferred tax liabilities
Net defined benefit liability
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Minority interests
Total net assets
Total liabilities and net assets

-6-

As of
December 31, 2014

45,661
127,384
10,0004,315

49,663
129,648
10,0001,905

14,895

12,075

949
8,563
415
10,734
3,516
123
2,438
2,897
18,820250,714

729
7,824
－
3,856
4,389
442
－
1,933
21,988244,455

45,832
177,004
1,510
1,976
4,042
449
284
1,878
232,979
483,694

44,082
205,307
1,359
2,025
3,924
515
49
2,179
259,443
503,898

84,397688
52,567(17,999)
119,654

84,397635
61,726(14,806)
131,952(7,443)38
13,535(357)
5,772
10,533
135,960
619,654(6,498)16
16,728(305)
9,940
11,051
152,945656,843

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]Quarterly Consolidated Statements of Income(Amount: million yen)
FY2013 first three months(From April 1, 2013
to December 31, 2013)
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Foreign exchange gain
Other
Total non-operating income
Non-operating expenses
Interest expenses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
State subsidy
Gain on sales of investment securities
Compensation income
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Impairment loss
Loss on sales of investment securities
Loss on reduction of non-current assets
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income

FY2014 first three months(From April 1, 2014
to December 31, 2014)

222,619
156,725
65,89355,598
10,295

240,101
166,135
73,96660,23913,726

579
1,866
2,037
1,178
5,662

552
1,596
6,327
1,385
9,862

2,926
－
1,121
4,047
11,910

3,033
122
1,942
5,098
18,490

209
544
1,263
742
361
3,120

637
7
3,402
34
18
4,099

215
1
－
530
258
1,006
14,024
9,640
(437)
9,203
4,821
328
4,493

238
12
1,894
－
319
2,465
20,124
7,753(2,541)
5,211
14,913392
14,520[Qarterly Consolidated Statements of Comprehensive Income](Amount: million yen)
FY2013 first three months(From April 1, 2013
to December 31, 2013)
Income before minority interests
Other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to owners of the parent
Comprehensive income attributable to minority interests-7-

FY2014 first three months(From April 1, 2014
to December 31, 2014)

4,821

14,913

9,057－
11,845－－20,902
25,724
24,623
1,100

946
(22)
3,217
52
(27)
4,166
19,07918,688390

(3) Notes Regarding Consolidated Financial Statement(Notes regarding going concern)
N/A(Notes regarding significant changes in the amount of shareholders’ equity)
N/A(Segment Information)Ⅰ

FY2013 (From April 1, 2013 to December 31, 2013)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

163,394

38,415

20,630222,441

178

222,619－

222,619(2)Inter-segment sales
and transfers

1,142

5,720

484

7,347

26

7,373

(7,373)－

Total

164,536

44,13621,115

229,788204

229,993(7,373)

222,619

Segment profit

15,2186,202(2,281)

19,139162

19,302(9,006)

10,295(Notes)
1.
2.

3.
2.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (9,006) million yen includes elimination of inter-segment transaction of(1,374) million yen and corporate cost of (7,632) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment(Significant Change in Goodwill)
Regarding Medical-Related Business, we acquired the share of Nichihos Co., Ltd. and its 10 subsidiaries toinclude them in the scope of consolidation. In accordance with it, goodwill increased 6,705million yen from the endof the previous year.

-8-

Ⅱ

FY2014 (From April 1, 2014 to December 31, 2014)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

175,364

42,966

21,686240,01783

240,101－

240,101(2)Inter-segment sales
and transfers

1,173

6,294

533

8,002

26

8,028

(8,028)－

Total

176,537

49,26122,220248,019110

248,129(8,028)240,101

Segment profit

17,664

8,572(2,205)24,031

104

24,135(10,408)

13,726(Notes)1.
2.

3.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (10,408) million yen includes elimination of inter-segment transaction of(2,052) million yen and corporate cost of (8,356) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Changes in Reportable Segments(1) Effective from this reporting period, Nipro Glass India PVT. LTD., Nipro Tube Glass PVT. LTD., Nipro Glass Americas
Corporation, Nipro Glass France S.A.S., Nipro Glass Belgium N.V., Nipro Pharma Glass AG, Nipro Glass Germany AG,
Nipro Sterile Glass Germany AG, Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd., Jilin Nipro Jiaheng
Pharmaceutical Packaging Co., Ltd. and Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd., OOO Ural Glass
Plant and Puyang City Changda Glass Co., Ltd. are reclassified from Medical-Related Business to Glass-Related
Business with current review of organization system in Nipro group.
Segment information in the current quarterly period is based on this reclassification.
(2) Effective from the first period ended June 30, 2014, the calculation method of retirement benefit obligations and service
costs in business segment was changed following the changes in accounting policy.
This change had no impact to profit and loss.
3. Information on Impairment Loss on Fixed Assets and on Goodwill by Reportable Segment
N/A-9-